Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSome people starting Wegovy notice changes to bleeding patterns — heavier periods, occasional spotting, or small bleeds at the injection site. In most cases these are explainable and temporary, but knowing which is which matters. Wegovy (semaglutide) is a prescription-only medicine reviewed by a clinician before and during every course of treatment, and any bleeding concern worth losing sleep over is worth raising with your prescriber promptly. This page sets out what the evidence actually says, keeps the speculation out of it, and tells you clearly when to seek help.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Picture this: you've just done your weekly Wegovy shot, pulled the pen away, and there's a small bead of blood or a faint bruise forming under the skin. Unsettling the first time, but almost always unremarkable. The needle passes through skin and subcutaneous tissue, and small capillaries in that layer can catch. A brief press with a clean piece of cotton settles it within a minute or two in the vast majority of cases.
Rotating your injection sites (abdomen, outer thigh, upper arm) reduces the chance of hitting an already-irritated spot. If you're finding the same site bleeds repeatedly, moving to a fresh area usually resolves it. For detailed guidance on technique, our page on bleeding after a Wegovy shot covers the practical side in more depth, and what counts as a normal bleed from the injection site explains when to treat it as a sign to call someone.
One thing worth setting aside: the idea that any blood after an injection means the medicine isn't working, or that you've done it wrong. Neither is true. A small bleed at the site has no bearing on how much semaglutide you've absorbed.
Heavier, lighter, or irregular periods are among the changes some women report after starting semaglutide. This is worth being honest about: the Wegovy SmPC does not list menstrual irregularity as a recognised adverse effect, and no large trial has confirmed a direct pharmacological link between semaglutide and changes to the menstrual cycle.
What is well-established is that significant weight loss (the kind Wegovy can produce) does affect hormones, including oestrogen and the hormones that regulate ovulation. Fat tissue stores and produces oestrogen; as body fat changes, hormone levels shift, and periods can change with them. That mechanism is documented and understood. So when women ask whether Wegovy can directly cause bleeding changes, the honest answer is: weight loss almost certainly plays a larger role than the drug itself, though individual responses vary.
If your periods become unusually heavy, last longer than normal for you, or you experience bleeding between periods, report this to your GP or prescriber. Don't assume it's just the treatment settling. The semaglutide overview on our site covers the broader side-effect profile, including what the NHS patient information says.
Nosebleeds come up in online forums alongside almost every medicine, and Wegovy is no exception. The licensed prescribing information for semaglutide does not identify epistaxis (nosebleeds) as a known side effect. Dehydration (which can occur if gastrointestinal side effects like nausea or vomiting are significant) dries out nasal membranes and makes small bleeds more likely. That's a plausible indirect route rather than a direct drug action.
If you're experiencing frequent nosebleeds alongside GI symptoms, staying well hydrated is the first practical step. Our page on dehydration and Wegovy explains the mechanism and what to watch for. Separately, our page specifically on nosebleeds and Wegovy looks at this question in more detail.
If nosebleeds are frequent, heavy, or not explained by dehydration or dry air, tell your GP. That's not an overreaction; it's the right call.
Most bleeding connected to Wegovy treatment is minor and has a straightforward explanation. But some presentations need same-day or emergency assessment, not a note saved for the next review. Contact a clinician the same day if you notice: vomiting blood or material that looks like coffee grounds; black, tarry or dark-red stools; blood in urine; prolonged or unusually heavy vaginal bleeding; or any unexplained bruising that's spreading or worsening.
These could indicate bleeding in the gastrointestinal tract or another site that requires investigation. The MHRA's Yellow Card scheme at yellowcard.mhra.gov.uk allows anyone to report suspected side effects from medicines, including unexpected bleeding, and the NHS patient information for semaglutide at nhs.uk/medicines/semaglutide lists the full set of recognised side effects to watch for.
If you take anticoagulants such as warfarin or apixaban, your prescriber needs to know about your Wegovy treatment from the start, monitoring requirements may change as your weight and diet shift. This is a conversation for your GP and the clinician overseeing your weight management, not a decision to make alone. If you have questions about whether Wegovy is appropriate for your full medical picture, our prescribers review every consultation personally. You can check your eligibility through a free clinical consultation with no obligation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.